NDA 021977 · Takeda Pharms USA
Vyvanse
Lisdexamfetamine Dimesylate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Feb 23, 2007
Approved uses
10
Original approval plus efficacy supplements
Registered trials
117
33 Phase 3, 5 recruiting
FAERS reports
33,465
13,613 serious, 307 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing VYVANSE, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout VYVANSE treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) , Drug Abuse and Dependence (9.2) ] . WARNING: ABUSE, MISUSE, AND ADDICTION See...
What it is approved for
From the label in effect Apr 30, 2026.
VYVANSE ® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1) ]. Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2) ] . VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of ( 1 ): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use : The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ) VYVANSE is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established ( 5.2 ) Limitations of Use: The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ] . VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established [see Warnings and Precautions (5.2) ] .
Mechanism: Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 2021 Supplement 46 · Efficacy · priority review LabelLetter
- Oct 14, 2016 Supplement 41 · Efficacy LetterLabel
- Jan 30, 2015 Supplement 37 · Efficacy · priority review LabelReviewLetter
- Apr 26, 2013 Supplement 27 · Efficacy Pediatric Medical ReviewPediatric Statistical ReviewLabel
- Jan 31, 2012 Supplement 22 · Efficacy LabelLetter
- Nov 10, 2010 Supplement 16 · Efficacy LetterLabel
- Apr 5, 2010 Supplement 10 · Efficacy LabelLetter
- May 22, 2009 Supplement 7 · Efficacy LabelLetter
- Apr 23, 2008 Supplement 1 · Efficacy LabelLetter
- Feb 23, 2007 Original approval · Type 1 - New Molecular Entity NovelReviewOther Important Information from FDAPediatric Medical Review
7 products under this application
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 60MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 20MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 50MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 10MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 40MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 70MG · CAPSULE, ORAL · Prescription · TE AB
- VYVANSE · LISDEXAMFETAMINE DIMESYLATE 30MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lisdexamfetamine Dimesylate" as an intervention, any sponsor and status, largest first.
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
- Open Label Extension in Adults With Binge Eating Disorder (BED)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01657019 · 604 participants · Start Aug 21, 2012 · Primary completion Oct 21, 2014
Drug: Lisdexamfetamine dimesylate · For: Binge Eating Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 89 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552902 · 549 participants · Start Apr 3, 2012 · Primary completion May 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Tucson, Arizona; Little Rock, Arkansas · 95 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552915 · 464 participants · Start Apr 17, 2012 · Primary completion Jan 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; National City, California · 79 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,768
- fatigue2,100
- off label use2,063
- anxiety1,851
- headache1,805
- nausea1,597
- product availability issue1,583
- insomnia1,505
- depression1,415
- feeling abnormal1,368
- product use issue1,335
- disturbance in attention1,284
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 300 |
| 2008 | 974 |
| 2009 | 1,147 |
| 2010 | 431 |
| 2011 | 377 |
| 2012 | 415 |
| 2013 | 502 |
| 2014 | 1,419 |
| 2015 | 2,219 |
| 2016 | 3,132 |
| 2017 | 1,872 |
| 2018 | 1,904 |
| 2019 | 1,777 |
| 2020 | 1,804 |
| 2021 | 1,700 |
| 2022 | 2,503 |
| 2023 | 3,169 |
| 2024 | 3,256 |
| 2025 | 2,700 |
| 2026 | 1,864 |
Recalls
1 FDA enforcement reports for this application.
Sep 2, 2016 · Class III · Terminated
Presence of Foreign Tablets/Capsules
Shortages
FDA's drug shortage list.
Current · updated Nov 2, 2026
Vyvanse, Capsule, 60 mg (NDC 59417-106-10).
Current · updated Nov 2, 2026
Vyvanse, Capsule, 70 mg (NDC 59417-107-10).
Current · updated Nov 2, 2026
Vyvanse, Capsule, 10 mg (NDC 59417-101-10).
Current · updated Nov 2, 2026
Vyvanse, Capsule, 40 mg (NDC 59417-104-10).
Current · updated Nov 2, 2026
Vyvanse, Capsule, 50 mg (NDC 59417-105-10).
Current · updated Nov 2, 2026
Vyvanse, Capsule, 20 mg (NDC 59417-102-10).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyvanse (Lisdexamfetamine Dimesylate)
2024 spending
$88.8M
Beneficiaries
41,415
212,410 claims
Per beneficiary
$2,145
$12.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $95,861,742 |
| 2021 | $108,096,030 |
| 2022 | $127,207,219 |
| 2023 | $138,990,768 |
| 2024 | $88,828,576 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of the safety of lisdexamfetamine dimesylate.
Coghill DR, Caballero B, Sorooshian S, et al. · CNS Drugs 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD.
Madaan V, Bhaskar S, Donnelly GAE, et al. · J Atten Disord 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
Schein J, Cloutier M, Gauthier-Loiselle M, et al. · J Comp Eff Res 2024 · Comparative Study, Randomized Controlled Trial
- Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies.
Berger G, Corris JD, Fields SE, et al. · Biomolecules 2023 · Systematic Review, Research Support, U.S. Gov't, Non-P.H.S.
- Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
Ichikawa H, Miyajima T, Yamashita Y, et al. · J Child Adolesc Psychopharmacol 2020 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.
Faraone SV · J Atten Disord 2012 · Meta-Analysis, Research Support, N.I.H., Extramural
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.